Cancer Gene Therapy

Combination Immunogene Therapy Effective In Glioblastoma Model

Published in Gene Therapy Weekly, July 21st, 1997

Vaccination with irradiated tumor cells transduced with a combination of immunogenes resulted in an immune response that inhibited tumor growth in a mouse-human glioblastoma multiforme model.

Despite advances in cancer therapeutics, the mean survival time for patients diagnosed with the central nervous system neoplasm, glioblastoma multiforme, is less than one year. Recent gene therapy approaches to this neoplasm have focused on suicide gene therapy using the herpes simplex virus type-1 thymidine kinase gene followed by the administration of ganciclovir. Although this system shows some promise, its in situ application remains problematic.

Exploring...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-07-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry